Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Literature
1.
Critical considerations on the combined use of 18F-FDG and 18F-fluoride for PET assessment of metastatic bone disease (authors Gang Cheng & Thomas C. Kwee & Sandip Basu & Abass Alavi) Eur J Nucl Med Mol Imaging (2013) 40:1141–1145 doi:10.​1007/​s00259-013-2459-y
2.
Iagaru A, Mittra E, Mosci C, Dick DW, Sathekge M, Prakash V, et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med. 2013;54:176–83. doi:10.​2967/​jnumed.​112.​108803.PubMedCrossRef
3.
Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med. 2009;50:501–5. doi:10.​2967/​jnumed.​108.​058339.PubMedCrossRef
4.
Lin F, Rao J, Mittra E, Nallapareddy K, Chengapa A, Dick D, et al. Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging. 2012;39:262–70.PubMedCrossRef
5.
Bailey D. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med. 2010;51:165–6.PubMedCrossRef
6.
Basu S, Rao R. Combined (18)F-FDG and fluoride approach in PET/CT imaging: is there a clinical future? J Nucl Med. 2010;51:165.PubMedCrossRef
7.
8.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
9.
Ben Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:408–15.PubMedCrossRef
10.
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168–76.PubMedCrossRef
11.
Iagaru A, Mittra E, Dick D, Gambhir S. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252–9.PubMedCrossRef
12.
Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol. 2003;32:201–8.PubMedCrossRef
13.
Jadvar H, Pinski J, Conti P. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep. 2003;10:1485–8.PubMed
14.
Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara N, Sato H, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;26:138–45.PubMedCrossRef
15.
Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637–43.PubMedCrossRef
16.
Krüger S, Buck A, Mottaghy F, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807–12.PubMedCrossRef
17.
Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–4.PubMed
18.
Jones MD, Pais MJ, Omiya B. Bony overgrowths and abnormal calcifications about the spine. Radiol Clin North Am. 1988;26:1213–34.PubMed
19.
Sampath S, Sampath S, Lutz A, Willmann J, Mittra E, Gambhir S, et al. Evaluation of NaF PET/CT, FDG PET/CT, combined NaF/FDG PET/CT and CT alone for detection of bone metastases. J Nucl Med. 2012;53 Suppl 1:586, abstract.
20.
Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253–8.PubMed
21.
Richmond K, McLean N, Rold T, Szczodroski A, Dresser T, Hoffman T. Optimizing a F-18 NaF and FDG cocktail as a preclinical cancer screening tool for molecular imaging. J Nucl Med. 2011;52 Suppl 1:2455. Abstract.
22.
Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.PubMed
23.
Adams M, Turkington T, Wilson J, Wong T. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.PubMedCrossRef
24.
Delbeke D, Coleman RE, Guiberteau M, Brown M, Royal H, Siegel B, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed
25.
Boellaard R, O’Doherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCrossRef
26.
27.
Hillner B, Siegel B, Liu D, Shields A, Gareen I, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–61.PubMedCrossRef
28.
Even Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.PubMedCrossRef
29.
Li Y, Schiepers C, Lake R, Dadparvar S, Berenji G. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50:128–39.PubMedCrossRef
30.
Kazama T, Swanston N, Podoloff D, Macapinlac H. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–11.PubMedCrossRef
31.
Niederkohr R. Technical feasibility vs. clinical utility: a question of “can we?” vs. “should we?”. Eur J Nucl Med Mol Imaging. 2012;39:260–1.PubMedCrossRef
32.
Metadata
Title
Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies
Authors
Andrei Iagaru
Camila Mosci
David W. Dick
Mike Sathekge
Paula Lapa
Joao M. de Lima
Sanjiv Sam Gambhir
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2556-y

Other articles of this Issue 12/2013

European Journal of Nuclear Medicine and Molecular Imaging 12/2013 Go to the issue

Original Article

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma

Letter to the Editor

Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity: further comments

Original Article

Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer

Original Article

The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET

Original Article

Gated SPECT evaluation of left ventricular function using a CZT camera and a fast low-dose clinical protocol: comparison to cardiac magnetic resonance imaging

Editorial Commentary

Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?